Forbes October 2, 2024
There is high demand for diabetes and obesity medications known as glucagon-like peptide-1 agonists, or GLP-1s. In conjunction with an appropriate diet and exercise regimen, GLP-1s can provide substantial health benefits to patients. Prior to several GLP-1s becoming popular obesity therapeutics, the class of drugs had been in use for many years in the treatment of type 2 diabetes. And a GLP-1 named Wegovy (semaglutide) secured a supplemental cardiovascular indication from the Food and Drug Administration this spring. More supplemental indications for GLP-1s could in the offing in the chronic kidney disease area as well as non-alcoholic steatohepatitis, or NASH.
But thus far real-world evidence on weight loss from the use of GLP-1s not as robust as the clinical trial...
Today's Sponsors
Today's Sponsor